Last updated: 2026-09-14 05:44:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $143,96, with a market capitalisation of $355,10B and a P/E ratio of 111,91. Over the past 52 weeks, its price has ranged from $77,58 to $156,92. This page covers its latest market performance, valuation, price trends and company information.
$355,10B | |
$145,52 | |
$156,92 | |
$15,32 | |
$144,71 | |
6,29M | |
10,38M | |
111,91 | |
$156,92 | |
$77,58 | |
2,34% | |
-- |
Merck & Co., Inc. (MRK) last closed at $144,71 as of 2026-09-11 23:58:00, unchanged from the previous close of $144,71.
During the latest regular trading session, MRK traded between $15,32 and $156,92, with a volume of 6,29M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $151,64 to $143,96, representing a decline of 5,07% ($7,68).
The stock traded between $143,68 and $152,80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7,97 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83,7%
MRK is currently trading at $143,96, placing it 83,7% of the way from its 52-week low of $77,58 to its 52-week high of $156,92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.